Please ensure Javascript is enabled for purposes of website accessibility

Why Bionano Genomics Stock Is Tumbling Today

By Keith Speights - Apr 16, 2021 at 11:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No news; just run-of-the-mill volatility.

What happened

Shares of Bionano Genomics (BNGO 0.00%) were tumbling 6.7% lower as of 11:10 a.m EDT on Friday. The company didn't report any news nor were there other developments that would explain the stock's decline. Instead, today's drop appears to be due to the volatility that's relatively typical for the stock.

So what

When a high-flying growth stock like Bionano sinks for no apparent reason, the best thing for investors to do is focus on the fundamentals of the company's business. For Bionano, the fundamentals revolve around its Saphyr genomic sequencing system.

DNA with reddish background

Image source: Getty Images.

Saphyr supports structural variation analysis that's especially helpful in cytogenetic research (the study of changes in chromosomes). Bionano's installed base of Saphyr systems totaled 97 at the end of 2020. Even during the pandemic, the company was able to increase its installed base by nearly one-third. 

Bionano generates revenue from instrument sales. However, over the longer term as its installed base size grows, sales of consumables including chips and reagents is where the company should make even more money.

Now what

One of the most important ways for Bionano to increase its Saphyr installed base is to roll out more laboratory-developed tests (LDTs) for the system. The company should achieve significant progress toward this goal in the coming months.

Bionano expects to receive accreditation for LDTs for acute lymphocytic leukemia and facioscapulohumeral muscular dystrophy in certain European markets by the end of the second quarter. It also plans to launch prenatal assays and expand its menu of pediatric assays in the third quarter.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bionano Genomics, Inc. Stock Quote
Bionano Genomics, Inc.
$3.60 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.